biotech / news / / Reuters
Auvelity, approved in 2022 for depression, is Axsome's top-selling product.
Auvelity is now newly approved for treating agitation related to Alzheimer's disease.
KEY POINTS
- Auvelity is unlikely to receive the black box warning typically required for antipsychotics.
- Axsome expects to launch Auvelity's Alzheimer's indication in June at the same list price.
- Data from four late-stage trials showed Auvelity delayed relapse and reduced symptom worsening.
COMPANIES
Summarized by Newsio from Reuters. How we summarize →